Warburg Pincus has acquired a 50% co-control stake in Polyplus from ArchiMed, executing a flagship LBO in the European mid-cap space. The transaction structure is characterized by a significant reinvestment from the incumbent sponsor, ArchiMed, ensuring that both private equity firms hold equal equity stakes and voting rights post-closing. To finance this acquisition, a bespoke unitranche debt facility was arranged and provided by Tikehau Capital and Goldman Sachs. The definitive agreement was signed following supreme execution certainty and intense competitive tension prior to the pandemic-induced market slowdown. For the incoming sponsor, this transaction represents a highly sought-after platform investment in the resilient and fast-growing bioprocessing sector. The deal allows the sponsors to capitalize on the secular growth of gene and cell therapies, as well as an intensified global focus on vaccine development. ArchiMed’s decision to roll over significant equity highlights a strong conviction in the asset's continued value-accretive trajectory and untapped international potential. By joining forces, the consortium provides Polyplus with extensive financial backing and dry powder to accelerate its geographical expansion, scale up its manufacturing capabilities, and potentially drive sector consolidation through targeted add-on acquisitions. The target has demonstrated exceptional financial momentum, underpinned by a highly scalable business model. This landmark transaction establishes a robust benchmark valuation for premium life sciences suppliers. The intense competitive dynamic during the auction process, coupled with the ability to secure unitranche financing from premier lenders, underscores the sustained appetite of mega-cap funds for high-quality, non-cyclical healthcare assets.

On September 19, 2016, ArchiMed completed the acquisition of a majority stake in Polyplus Transfection, a prominent player in the biologics delivery space. The transaction was executed as a proprietary deal, seamlessly completed outside of any formal auction process, and was heavily supported by the existing management team. This strategic move represents a textbook platform investment for the private equity firm, executed through its Med 1 fund, capitalizing on their deep sector expertise. The strategic rationale behind this transaction is deeply rooted in the strong secular growth currently observed across biologics-based therapeutics and cell therapies. By acquiring this niche champion, the firm aims to leverage its extensive global healthcare network to accelerate international expansion and push proprietary product development into a higher gear. The deal is expected to be highly value-accretive, combining vast financial resources and operational capabilities with specialized proprietary transfection technology. Market implications are substantial, signaling increased sector consolidation within the highly fragmented life sciences supply chain and highlighting the premium placed on specialized reagent manufacturers.